登录 | 注册    关注公众号  
微信公众号
搜索
 > 【FGF basic】

FGF basic信息

英文名称:Fibroblast growth factor 2
中文名称:成纤维细胞生长因子2
靶点别称:FGF-2,Heparin-binding growth factor 2,Basic fibroblast growth factor,FGFB,bFGF,HBGF-2,FGF2,Fibroblast Growth Factor 2 (Basic),Basic Fibroblast Growth Factor BFGF,Prostatropin,Fibroblast Growth Factor 2
上市药物数量:2
临床药物数量:3
最高研发阶段:批准上市

FGF basic产品列表

ACROBiosystems提供将现有的目录Non-GMP级别(RUO或Premium级别)蛋白产品快速转化为GMP级别的升级服务,也可以从零开始为您提供GMP级别蛋白从头定制化开发服务>>点击立即咨询GMP级别蛋白产品定制服务~

 
评论(0)
 

FGF basic 分子别名

FGF2,BFGF,FGFB,FGF basic,HBGF-2

FGF basic 分子背景

FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway. FGF basic has been isolated from a number of sources, including neural tissue, pituitary, adrenal cortex, corpus luteum, and placenta. This factor contains four cysteine residues, but reduced FGF basic retains full biological activity, indicating that disulfide bonds are not required for this activity. bFGF is a critical component of human embryonic stem cell culture medium; the growth factor is necessary for the cells to remain in an undifferentiated state, although the mechanisms by which it does this are poorly defined. It has been demonstrated to induce gremlin expression which in turn is known to inhibit the induction of differentiation by bone morphogenetic proteins. It is necessary in mouse-feeder cell dependent culture systems, as well as in feeder and serum-free culture systems.

FGF basic 前沿进展

FGF basic上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Thalidomide 沙利度胺 NSC-66847; NSC-527179; K-17; VP-02 批准上市 Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Japan 麻风结节性红斑 Fujimoto Pharmaceutical 1982-01-01 华氏巨球蛋白血症, 肉瘤, 前列腺癌, 蛛网膜炎, 原发性硬化性胆管炎, 胃肠道出血, 骨肉瘤, 慢性胰腺炎, 眼癌, 尤因肉瘤, 套细胞淋巴瘤, 前列腺炎, 溃疡性结肠炎, 结直肠癌, 原始神经外胚层肿瘤, 结节性红斑, 麻风结节性红斑, 子宫内膜癌, 阑尾肿瘤, 盆腔疼痛, 血管发育不良, 胶质瘤, 非霍奇金淋巴瘤, 肝细胞癌, 肌萎缩性侧索硬化, 血管畸形, 克罗恩病, 癌前状态, 胞内分枝杆菌感染, 特发性肺纤维化, 白血病, 边缘带B细胞淋巴瘤, B-细胞淋巴瘤, 肝癌, 咳嗽, 遗传性出血性毛细血管扩张, 分支杆菌感染, 横纹肌肉瘤, 动静脉畸形, 炎症性肠疾病, 口腔炎,口疮, 胃窦血管扩张, 强直性脊柱炎, 骨髓增生异常综合征, HIV感染, 新型冠状病毒肺炎, 肿瘤, 霍奇金病, 肾母细胞瘤, 门静脉高血压, 黑粪症, 弥漫性大B-细胞淋巴瘤, 多发性骨髓瘤, 辐射损伤, 结核分枝杆菌感染, 子宫内膜异位症, 直 详情

FGF basic临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Muparfostat sodium PI-88 临床三期 澳洲国立大学 肝细胞癌 详情
Fibroblast growth factor 2 gene therapy (ID Pharma) SeV-10101; SEV-10101; DVC-10101; BF-30 临床一期 Dnavec 动脉闭塞性疾病 详情
Squalamine OHR-102; MSI-1256F Genaera 详情

消息提示

请输入您的联系方式,再点击提交!

确定